Cana­di­an gene ther­a­py biotech en­Gene starts trad­ing on Nas­daq af­ter com­plet­ing For­bion SPAC deal

Gene ther­a­py start­up en­Gene be­came a pub­lic biotech on Wednes­day af­ter com­plet­ing its com­bi­na­tion with For­bion Eu­ro­pean Ac­qui­si­tion, a blank check com­pa­ny formed in 2021.

The Mon­tre­al and Boston non-vi­ral gene ther­a­py mak­er is one of the few life sci­ences com­pa­nies to com­plete a SPAC deal this year, as the al­ter­na­tive list­ing route large­ly went out of vogue af­ter a surge in pop­u­lar­i­ty in 2020. En­Gene $EN­GN com­menced trad­ing on Nas­daq and reeled in about $138 mil­lion in pro­ceeds to bankroll an on­go­ing piv­otal tri­al that’s ex­pect­ed to have an in­ter­im read­out in the mid­dle of next year, which would pave the way to a po­ten­tial BLA fil­ing in mid-2025, CEO Ja­son Han­son told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER